Unknown

Dataset Information

0

Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer.

ABSTRACT:

SUBMITTER: Webster EM 

PROVIDER: S-EPMC7640901 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer.

Webster Emily M EM   Zeybek Burak B   Tymon-Rosario Joan J   Santin Alessandro D AD  

Oncoscience 20200608 9-10

Similar Datasets

Unknown Antibody-Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release.
| S-EPMC9812893 | biostudies-literature
Unknown The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan-effectiveness, pitfalls and promises.
| S-EPMC9347060 | biostudies-literature
Unknown Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
| S-EPMC7303962 | biostudies-literature
Unknown Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas.
| S-EPMC12423748 | biostudies-literature
Unknown Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer.
| S-EPMC11247314 | biostudies-literature
Unknown Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?
| S-EPMC8350658 | biostudies-literature
Unknown Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
| S-EPMC4673178 | biostudies-literature
Unknown Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
| S-EPMC8259232 | biostudies-literature
Unknown Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer.
| S-EPMC11185941 | biostudies-literature
Unknown Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
| S-EPMC6976591 | biostudies-literature